Medtronic (MDT +0.3%) receives FDA and CE Mark approval for its Arctic Front Advance cardiac...
Friday, August 24, 2012, 1:32 PM ETMedtronic (MDT +0.3%) receives FDA and CE Mark approval for its Arctic Front Advance cardiac cryoballoon for the treatment of paroxysmal atrial fibrillation. MDT has the only cryoballoon system currently on the market worldwide, which is purported to provide a more efficient approach to treating the condition than through point-by-point, radiofrequency ablation.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles